ArticleCancer immunology, immunotherapy : CII2021

Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors.

Khanh T Do et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.